bioAffinity Technologies Reports Record 300% Surge in CyPath® Lung Sales for April
Summary
bioAffinity Technologies announced record monthly unit sales for its CyPath® Lung diagnostic test in April, with nearly 300% year-over-year growth, providing a crucial operational boost amidst ongoing financial challenges and a short cash runway.
Key Events
-
Record Monthly Sales Achieved
Unit sales for the CyPath® Lung diagnostic test reached a record high in a single month during April 2026, based on preliminary unaudited data.
-
Significant Year-Over-Year Growth
April 2026 unit sales increased by nearly 300% compared to the same period in 2025, continuing the accelerating adoption trend seen in Q1 2026.
-
CEO Highlights Accelerating Adoption
President and CEO Maria Zannes noted that CyPath® Lung usage continues to accelerate rapidly as its value in lung cancer diagnosis is increasingly recognized by physicians.
-
Operational Strength Amidst Financial Need
This strong operational performance provides a positive counterpoint to the company's recently disclosed going concern warning and critical cash runway through June 2026, potentially aiding future financing efforts.
Analysis
This filing reports a significant acceleration in sales for the company's flagship diagnostic product, CyPath® Lung. The nearly 300% year-over-year growth in April unit sales, following a 146% increase in Q1, demonstrates strong operational momentum. This positive news is critical for bioAffinity Technologies, which recently disclosed a going concern warning and a cash runway extending only through June 2026. Sustained sales growth could improve the company's position in securing much-needed financing to extend its operational runway.
At the time of this filing, BIAF was trading at $2.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $0.69 to $15.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.